Nurix Therapeutics. has filed a patent for compounds that can degrade Bruton’s tyrosine kinase (BTK) through a ubiquitin proteolytic pathway. The patent also covers pharmaceutical compositions containing these compounds and their use in treating autoimmune diseases and cancer. The method involves orally administering a bifunctional compound to a subject in need, effectively treating or preventing the disease or cancer. GlobalData’s report on Nurix Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nurix Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Nurix Therapeutics's grant share as of September 2023 was 5%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a method of treating autoimmune diseases or cancer using a bifunctional compound
A recently filed patent (Publication Number: US20230227471A1) describes a method for treating or preventing autoimmune diseases or cancer in a subject. The method involves orally administering a bifunctional compound that can induce the proteolytic degradation of Bruton's tyrosine kinase, an enzyme associated with these conditions. The amount of the compound administered is effective in treating or preventing the autoimmune disease or cancer.
Additionally, the patent claims a method for degrading splenocyte Bruton's tyrosine kinase in a subject. By orally administering the bifunctional compound, the compound can effectively degrade the enzyme in the subject.
Furthermore, the patent claims a method for preventing B cell activation in a subject. By orally administering the bifunctional compound, the compound can effectively prevent the activation of B cells in the subject.
The patent also includes a list of compounds in Table 1, along with their pharmaceutically acceptable salts. These compounds are claimed to be effective in treating or preventing autoimmune diseases or cancer by inducing the proteolytic degradation of Bruton's tyrosine kinase.
It is important to note that the claims numbered 2-8, 10, and 12-122 have been canceled, indicating that they are no longer part of the patent application.
Overall, this patent application presents a method for treating or preventing autoimmune diseases or cancer by orally administering a bifunctional compound that can induce the proteolytic degradation of Bruton's tyrosine kinase. The inclusion of a list of specific compounds further supports the potential effectiveness of this method.
To know more about GlobalData’s detailed insights on Nurix Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
